IL-15 and cognate antigen successfully expand de novo-induced human antigen-specific regulatory CD4+ T cells that require antigen-specific activation for suppression

J Immunol. 2003 Dec 15;171(12):6431-41. doi: 10.4049/jimmunol.171.12.6431.

Abstract

An important prerequisite in using regulatory T cells for immunotherapy is their ex vivo expansion without loss of suppressor function. Human anergic regulatory T cells are expandable by Ag-specific stimulation in the presence of IL-2. IL-15, like IL-2, is a T cell growth factor that, in contrast to IL-2, stimulates survival of T cells. In this study, we examined whether IL-15 could be exploited as a superior growth factor of human CD4(+) anergic regulatory T cells that were generated by costimulation blockade. Next, IL-15, as compared with IL-2, was investigated with respect to expansion and function of these regulatory T cells. Optimal expansion required cognate allogeneic stimulation in the presence of exogenous IL-15. IL-15 resulted in enhanced survival that was paralleled by an increased number of Bcl-2-expressing cells. Moreover, IL-15 induced a distinct type of anergy characterized by hyperreactivity to IL-15, resulting in improved expansion. This is likely attributed to increased propensity of these cells to up-regulate both alpha- and gamma-chains of the IL-2 and IL-15 receptor. Notably, IL-15-expanded regulatory CD4(+) T cells suppressed both naive and memory T cells in a superior way. Immunosuppression required alloantigen-specific stimulation and appeared gamma-irradiation resistant and independent of IL-10, TGFbeta, or CTLA-4 interactions. These regulatory T cells were stable suppressors, mediating bystander suppression upon TCR stimulation, but leaving recall responses unaffected in the absence of cognate Ag. Finally, human naturally occurring regulatory CD4(+)CD25(+) T cells appeared important in generating regulatory T cells by costimulation blockade. In conclusion, IL-15-expanded, de novo-induced human anergic regulatory CD4(+) T cells are of interest in Ag-specific immunotherapy.

MeSH terms

  • Antibodies, Blocking / pharmacology
  • Antigens, CD / immunology
  • Antigens, Differentiation / physiology
  • B7-2 Antigen
  • Bystander Effect / immunology
  • CD4-Positive T-Lymphocytes / cytology
  • CD4-Positive T-Lymphocytes / immunology*
  • CD4-Positive T-Lymphocytes / metabolism
  • CD40 Antigens / immunology
  • CTLA-4 Antigen
  • Cell Division / immunology
  • Cells, Cultured
  • Clonal Anergy / immunology
  • Coculture Techniques
  • Epitopes, T-Lymphocyte / physiology*
  • Histocompatibility Antigens Class II / physiology*
  • Humans
  • Immunity, Innate
  • Immunologic Memory / immunology
  • Immunophenotyping
  • Interleukin-10 / physiology
  • Interleukin-15 / pharmacology
  • Interleukin-15 / physiology*
  • Interleukin-2 / pharmacology
  • Interphase / immunology
  • Intracellular Fluid / chemistry
  • Intracellular Fluid / immunology
  • Lymphocyte Activation / immunology*
  • Membrane Glycoproteins / immunology
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • Receptors, Antigen, T-Cell / metabolism
  • Receptors, Antigen, T-Cell / physiology
  • Receptors, Interleukin-2 / biosynthesis
  • Staining and Labeling
  • T-Lymphocyte Subsets / cytology*
  • T-Lymphocyte Subsets / immunology*
  • T-Lymphocyte Subsets / metabolism
  • Transforming Growth Factor beta / physiology
  • Up-Regulation / immunology

Substances

  • Antibodies, Blocking
  • Antigens, CD
  • Antigens, Differentiation
  • B7-2 Antigen
  • CD40 Antigens
  • CD86 protein, human
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Epitopes, T-Lymphocyte
  • Histocompatibility Antigens Class II
  • Interleukin-15
  • Interleukin-2
  • Membrane Glycoproteins
  • Proto-Oncogene Proteins c-bcl-2
  • Receptors, Antigen, T-Cell
  • Receptors, Interleukin-2
  • Transforming Growth Factor beta
  • Interleukin-10